PUBLIC COMPANY
save$KURAKura Oncology, Inc.
$KURA10.650.00%San Diego, CA, USupdated 2d ago
community read0 votes
pipeline
3
marketed
1
phase 3
1
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
1Phase 11Phase 31Marketed
Upcoming
no upcoming catalysts on record
Recent(90d)
view all catalysts →Active trials
- phase3Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- phase2First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
- phase1KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- phase1Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- phase1A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- phase1A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- phase2Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
- —Expanded Access to Ziftomenib
🐶 Hiring Signal
News
- Lilly cans early experimental obesity drug after ‘high bar’ not metEli Lilly has put the kibosh on an early-stage obesity drug after the candidate didn’t meet the pharma giant’s lofty expectations.fiercebiotech · 20d ago
- This week in charts: RA’s insatiable appetite, Novartis’ big slide and a reverse merger spreeRA Capital has already participated in four biotech financings in September. Meanwhile, Janus Henderson has been the year's most prolific backer of biotech reverse merger deals, according to Gilmar…biopharma_dive · 23d ago
- Encoded raises $275M series F for Dravet syndrome gene therapyEncoded Therapeutics’ lead asset ETX101 is a gene therapy being tested for Dravet syndrome. Phase 1/2 data showed substantial reductions in seizures.biospace · 24d ago
- Kura spins diabetes work into a Lilly-backed biotech startupCaspian Therapeutics aims to develop menin inhibitors, which have proven effective against leukemia, for diabetes and other cardiometabolic conditions.biopharma_dive · 25d ago
- Kura Oncology spins out diabetes pipeline with $50M and Lilly's helpKura Oncology, the maker of the menin inhibitor Komzifti, is spinning out its diabetes R&D to a new company that has attracted the attention of the leading pharma in the metabolic field. ...endpoints · 26d ago
- STAT+: Leukemia drug data suggested a different way to treat diabetes. A new biotech will test that ideaCaspian Therapeutics, is launching with $50 million in financing to develop menin inhibitors for diabetes and other cardiometabolic diseases.stat · 26d ago
- Caspian launches with $50M, Lilly support to advance disease-modifying diabetes betKura Oncology has spun out Caspian around KO-7246, which seeks to increase the number and activity of beta cells in the pancreas, in turn boosting insulin production in patients with diabetes.biospace · 26d ago
- Kura creates Lilly-backed spinout armed with $50M to advance next-gen diabetes therapyKura Oncology has spun out a biotech armed with $50 million in fresh funding to take forward a next-generation diabetes treatment.fiercebiotech · 26d ago
- AstraZeneca's breast cancer PDUFA delayed; Arrowhead aims at same obesity target as WavePlus news about Kailera, Alfasigma, Junshi and Kura. ⏰ FDA delays AstraZeneca’s camizestrant PDUFA date: The FDA has extended its PDUFA date for AstraZeneca’s breast cancer drug camizestrant, a few…endpoints · 4mo ago
Data sources
last refreshed 39m ago
Found something off?
comments(0)
5-min edit window · permanent after that